Ionis Pharmaceuticals, Inc.
Modulators of IRF4 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
Status:
Grant
Type:
Utility
Filling date:
1 Mar 2019
Issue date:
8 Feb 2022